Standard therapy and potential therapeutic targets for autoimmune hepatitis
10.3969/j.issn.1001-5256.2020.04.005
- VernacularTitle:自身免疫性肝炎的标准治疗和潜在治疗靶点
- Author:
Rui WANG
1
;
Qixia WANG
;
Xiong MA
Author Information
1. Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University & Shanghai Institute of Digestive Diseases, Shanghai 200001, China
- Publication Type:Research Article
- Keywords:
hepatitis， autoimmune;
therapeutics;
molecular targeted therapy
- From:
Journal of Clinical Hepatology
2020;36(4):737-742
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune hepatitis (AIH) is a liver inflammatory disease mediated by autoimmune response and may progress to liver failure and liver cirrhosis without treatment. The goal of AIH treatment is to achieve biochemical remission and histological remission. Currently immunosuppressant therapy is the standard therapy for AIH, i.e., prednisone/prednisolone alone or combined with azathioprine. For the patients who do not tolerate or have poor response to the standard therapy, second-line treatment regimen, including mycophenolate mofetil, can be considered. Recent studies have shown that various factors participate in the development and progression of AIH, such as immune function, gut microbiota, vitamin D, and mental state, which may become the potential therapeutic targets for AIH. This article reviews related studies on the standard therapies for AIH and highlights the potential therapeutic targets for AIH treatment.
